CenterBook Partners LP Lowers Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

CenterBook Partners LP trimmed its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 58.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,306,259 shares of the biopharmaceutical company's stock after selling 1,806,326 shares during the quarter. CenterBook Partners LP owned approximately 0.66% of Esperion Therapeutics worth $2,874,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ESPR. Cibc World Markets Corp acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $39,000. SJS Investment Consulting Inc. purchased a new stake in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Foundations Investment Advisors LLC increased its stake in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock worth $66,000 after buying an additional 9,872 shares in the last quarter. J.W. Cole Advisors Inc. acquired a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $66,000. Finally, SLT Holdings LLC purchased a new position in shares of Esperion Therapeutics in the fourth quarter valued at approximately $66,000. Hedge funds and other institutional investors own 47.39% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on ESPR. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 price target for the company. JMP Securities reiterated a "market outperform" rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, April 8th. Finally, HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Esperion Therapeutics currently has an average rating of "Hold" and an average target price of $6.58.

Remove Ads

Esperion Therapeutics Price Performance

Shares of ESPR stock traded up $0.02 during trading on Tuesday, hitting $1.02. 1,714,327 shares of the stock traded hands, compared to its average volume of 5,673,507. Esperion Therapeutics, Inc. has a 52-week low of $0.93 and a 52-week high of $3.94. The firm has a market capitalization of $200.82 million, a P/E ratio of -1.59 and a beta of 0.86. The firm's fifty day moving average price is $1.56 and its 200-day moving average price is $2.02.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.